Securities Code: 4506


Supplementary Financial Data
for the Year Ended－ March 31, 2009
I.
Consolidated
Financial
Highlights

1
II. Consolidated Statements of Income
3
III.
Consolidated
Balance
Sheets

6
IV. Group-to-Parent Ratios, Consolidated Subsidiaries, Numbers of Employees and MRs
8
V.
Quarterly
Business
Results
8
VI.
Non-Consolidated
Financial
Highlights

9
VII.
Shareholder
Positioning
10
VIII.
Development
Pipeline
11
IX. Profile of Major Products under Development
15
May 11, 2009

Dainippon Sumitomo Pharma Co., Ltd.
- Forecasts provided in this document are based on the management’s assumptions and beliefs, made in light of information available up to the day of announcement. Actual financial results may differ materially from those presented in this document, being dependent upon a number of factors. - All values are rounded. Therefore totals may not be consistent with aggregated figures.

1
I. Consolidated Financial Highlights

1. Highlights of the Statements of Income
(Billions of Yen)
Change (%)
Change (%)
Change (%)
Net sales
264.0
264.0
0.0
130.6
(2.8)
264.0
－
Cost of sales
99.4
103.7
4.4
52.2
(1.2)
106.5
2.7
SG&A expenses
124.8
129.1
3.5
65.6
3.6
132.5
2.6
SG&A expenses lessR&D costs
77.5
76.3
(1.6)
38.9
0.9
78.0
2.2
R&D costs
47.3
52.8
11.7
26.7
7.7
54.5
3.2
Operating income
39.8
31.2
(21.7)
12.8
(29.6)
25.0
(19.8)
Ordinary income
37.7
31.4
(16.6)
12.4
(31.9)
24.0
(23.6)
Net income
25.6
20.0
(21.9)
7.8
(28.2)
15.0
(25.0)
Notes: Cost of sales includes provision for (reversal of) reserve for sales returns.
Earnings per share (yen)
64.39
50.30
37.75
Return on equity (ROE)
8.2%
6.2%
4.6%
Payout ratio
28.0%
35.8%
47.7%
2. Highlights of the Balance Sheets
(Billions of Yen)
Total assets
399.8
391.3
(8.5)
Net assets
318.3
324.5
6.2
　
Shareholders' equity
318.2
324.4
6.2
Shareholders' equity ratio
79.6%
82.9%
As of
3/31/08
(A)
As of
3/31/09
(B)
(B) - (A)
Year ending 3/31/10
(Forecast)
Year ended 3/31/09
Year
ended
3/31/08
Six months ending9/30/09 (Forecast)
"Change(%)" represent ratio of changes from the corresponding period of the previous year.

3. Capital Expenditures and Depreciation
(Billions of Yen)
15.5
10.6
(4.9)
13.0
2.4
Depreciation and amortization
11.1
10.7
(0.4)
12.0
1.3
Year ending
3/31/10
(Forecast)
Change
Capital expenditures(including intangible assets)
Year ended
3/31/08
Year ended
3/31/09
Change

- Major capital expenditure projects for the year ending March 31, 2010
Integration of product formulations development functions in Technology Research & Development Division :

¥0.90 billion (total budget: ¥0.90 billion, to be completed in January 2010)

2
4. Highlights of the Statements of Cash Flows
(Billions of Yen)
Net cash provided by operating activities
32.5
26.3
(6.2)
Net cash used in investing activities
(51.0)
(21.3)
29.7
Net cash used in financing activities
(6.9)
(11.8)
(4.9)
56.3
49.5
(6.8)
Cash and cash equivalents at the endof period
Year ended
3/31/08
(A)
Year ended
3/31/09
(B)
(B)-(A)
・
(B):Repayment of long-term
debt (4.6 billion yen)
・
(A): Short-term loans to the
parent company (40 billion yen)・
(B): Purchase of property, plant
and equipment (13.6 billion yen) (new solid dosage form building at Suzuka Plant,etc.) Increased short-term loans to the parent company (10 billion yen)

3

II. Consolidated Statements of Income


1. Statements of Income
(Billions of Yen)
(B)-(A)
Change
(%)
Net sales
264.0
264.0
0.0
0.0
Overseas sales
24.5
22.1
(2.5)
(10.1)
Cost of sales
99.4
103.7
4.4
4.4
Gross profit
164.6
160.3
(4.3)
(2.6)
SG&A expenses
124.8
129.1
4.3
3.5
Labor costs
32.3
32.9
0.6
1.7
Advertising andpromotion costs
5.9
5.3
(0.6)
(10.1)
Sales promotion costs
9.4
10.8
1.4
14.6
Other costs
29.9
27.3
(2.6)
(8.6)
SG&A expenses less R&Dcosts
77.5
76.3
(1.2)
(1.6)
R&D costs
47.3
52.8
5.6
11.7
Operating income
39.8
31.2
(8.6)
(21.7)
Non-operating income
3.1
3.0
(0.1)
Non-operating expenses
5.2
2.7
(2.5)
Ordinary income
37.7
31.4
(6.3)
(16.6)
Extraordinary income
3.8
1.1
(2.7)
　
Reversal of reserve for loss
　
on litigation
－
1.1
1.1
　
Gain on sales of investment
　
securities
3.8
－
(3.8)
Extraordinary loss
－
0.3
0.3
　
Loss on valuation of
　
investment securities
－
0.3
0.3
41.5
32.2
(9.3)
(22.4)
Income taxes
15.8
12.2
(3.6)
Minority interests in net income
0.1
0.0
(0.1)
Net income
25.6
20.0
(5.6)
(21.9)
Note: Cost of sales includes provision for (reversal of) reserve for sales returns.
Year
ended
3/31/08
(A)
Year
ended
3/31/09
(B)
Income before income taxesand minority interests
(Positives)・
Sales of new products
(LONASEN®／AVAPRO®)・
Start of new contract
manufacturing(Negatives)・
NHI price revision
・
Decreased sales of
AMLODIN®
・
Rise in cost of sales ratio
(37.6%→39.3%) due to NHIprice revision and theapplication of "AccountingStandard for Measurementof Inventories"
・
Overseas clinical trials of
lurasidone in progress
・
Loss on disposal／valuation
of inventories included inCost of sales from currentperiod
・
Increase due to launch of
new products(LONASEN®／AVAPRO®)
・
Reversal of reserve based
on the appeal court'sdecision
2. Segment Information
(Billions of Yen)
Pharma
ceuticals
Other
products
Total
Pharma
ceuticals
Other
products
Total
Pharma
ceuticals
Other
products
Total
Pharma
ceuticals
Other
products
Total
Net sales
208.7
55.3
264.0
206.8
57.2
264.0
101.6
29.0
130.6
204.2
59.8 264.0
38.7
1.1
39.8
29.8
1.3
31.2
Operatingincome
Year ended
3/31/08
Year ended
3/31/09
Year ending 3/31/10
（
Forecast）
Six months ending
9/30/09（Forecast）

4

3. Sales of Major Products

Pharmaceuticals（Domestic） （Billions of Yen）
Brand name (Generic name)
Therapeutic indication
Year
ended
3/31/08
(A)
Year
ended
3/31/09
(B)
(B)-(A)
Change
(%)
Six
months
ending
9/30/09
(Forecast)
Year
ending
3/31/10
(Forecast)

AMLODIN
®
(amlodipine)
Therapeutic agent for hypertension and angina pectoris

63.6
57.9
(5.7)
(9.0%) 25.3 48.0

GASMOTIN
®
(mosapride citrate)
Gastroprokinetic

19.5
20.2
0.7 3.4% 10.4 21.0

PRORENAL
®
(limaprost alfadex)
Vasodilator

14.5
14.8
0.3 2.1% 7.7 15.5

MEROPEN
®
(meropenem)
Carbapenem antibiotic
14.8
14.8
0.0
0.1% 6.6
12.9

EBASTEL
®
(ebastine)
Antiallergic

11.1
10.6
(0.5)
(4.1%) 3.3 8.6

SUMIFERON
®

(interferon-α NAMALWA))
Natural alpha interferon

6.0
6.0
(0.0)
(0.7%) 3.0
6.0

GROWJECT
®
(somatropin)
Growth hormone

4.3
4.3
0.0
0.4%
2.3
4.6

DOPS
®
(droxidopa)
Norepinephrine-activating neural function ameliorant

4.1
3.8
(0.3)
(7.7%) 1.8
3.6

EXCEGRAN
®
(zonisamide)
Antiepileptic
3.5
3.6
0.0 0.9% 1.9 3.8

QVAR
TM
(beclomethasone
dipropionate)
Bronchial asthma
4.3
3.6
(0.7)
(16.7%) 1.4 3.0

GLIMICRON
®
(gliclazide)
Oral hypoglycemic
3.9
3.6
(0.3)
(8.4%)

1.7
3.4

LONASEN
®
(blonanserin)
Antipsychotic

―

3.4
3.4
―

2.8
6.5

MELBIN
®
(metformin)
Oral hypoglycemic

2.8
3.4
0.5
17.7%
1.9
3.9

AmBisome
®
(amphotericin B)
Therapeutic agent for systemic fungal infection
2.5
3.1
0.5 20.0%
1.9
4.3

ALMARL
®
(arotinolol)
Therapeutic agent for hypertension, angina pectoris and arrhythmia

3.2
3.0
(0.2)
(5.1%) 1.5
2.9

LULLAN
®
(perospirone)
Antipsychotic

3.0
2.8
(0.2)
(5.4%) 1.4
2.7

TAGAMET
®
(cimetidine)
H
2
-receptor antagonist

3.3
2.7
(0.5)
(16.1%) 1.2
2.4

SEDIEL
®
(tandospirone)
Serotonin-agonist antianxiety drug

3.0
2.7
(0.2)
(8.3%) 1.3
2.6

AVAPRO
®
(irbesartan)
Therapeutic agent for hypertension

―

1.5
1.5
―
2.1
6.0
New Products
TRERIEF
®
(zonisamide)
Parkinson’s disease drug

―
0.1
0.1
―

0.4
1.1